{
  "id": "626aec71e764a53204000041",
  "type": "summary",
  "question": "What is Tagsedi?",
  "ideal_answer": "Tagsedi is a second-generation antisense oligonucleotide with 2'-O-methoxyethyl modification designed to bind to the 3' untranslated region of the transthyretin mRNA in the nucleus of the liver cells.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32865784"
  ],
  "snippets": [
    {
      "text": "A new drug named inotersen (brand name Tagsedi), also known as IONIS-TTRRX, has been approved by the United States Food and Drug Agency, Health Canada, and European Commission in 2018, and introduced to the market for patients in stage 1 and stage 2 hATTR polyneuropathy. Inotersen is a second-generation antisense oligonucleotide with 2'-O-methoxyethyl modification designed to bind to the 3' untranslated region of the transthyretin mRNA in the nucleus of the liver cells. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32865784",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}